Role of FcRs in animal model of autoimmune bullous pemphigoid

Journal of Immunology

Volumn 177, Issue 5, 2006, Pages 3398-3405

  Zhao, Minglang ^a   Trimbeger, Mary E ^a   Li, Ning ^a   Diaz, Luis A ^a   Shapiro, Steven D ^b   Liu, Zhi ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIGEN BP180; ANTIGEN BP230; AUTOANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BLISTER; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME RELEASE; EXPERIMENTAL MODEL; FEMALE; HEMIDESMOSOME; INFLAMMATORY INFILTRATE; LEUKOCYTE ACTIVATION; MALE; MAST CELL DEGRANULATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NEWBORN; NONHUMAN; PEMPHIGOID; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE;

EID: 33747801066     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.5.3398     Document Type: Article

References (62)

1. Lever, W. F. 1953. Pemphigus. Medicine 32: 1-4.
2. Korman, N. J. 1993. Bullous pemphigoid. Dermatologic Clin. 11: 483-498.
3. Stanley, J. R. 1999. Bullous pemphigoid. In Fitzpatrick's Dermatology in General Medicine. I. M. Freedberg, A. Z. Eisen, K. Wolff, K. F. Austen, L. A. Goldsmith, and S. I. Katz, eds. McGraw Hill, New York, pp. 666-671.
4. Giudice, G. J., D. J. Emery, and L. A. Diaz. 1992. Cloning and primary structural analysis of the bullous pemphigoid autoantigen, BP-180. J Invest. Dermatol. 99: 243-250.
5. Ishiko, A., H. Shimizu, A. Kikuchi, T. Ebihara, T. Hashimoto, and T. Nishikawa. 1993. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J. Clin. Invest. 91: 1608-1615.
6. Hopkinson, S. B., K. S. Riddelle, and J. C. R. Jones. 1992. Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J. Invest. Dermatol. 99: 264-270.
7. Giudice, G. J., D. J. Emery. B. D. Zelickson, G. J. Anhalt, Z. Liu, and L.A. Diaz. 1993. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J. Immunol. 151: 5742-5750.
8. Zillikens, D., P. A. Rose, S. D. Balding, M. Olague-Marchan, J. M. Mascara, Jr., Z. Liu, L. A. Diaz, and G. J. Giudice. 1997. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J. Invest. Dermatol. 109: 573-579.
9. Emmerson, R. W., and E. Wilson-Jones. 1968. Eosinophilic spongiosis in pemphigus: a report of an unusual histological change in pemphigus. Arch. Dermatol. 97: 252-257.
10. Nishioka, K., K. Hashimoto, I. Katayama, C. Sarashi, T. Kubo, and S. Sano. 1984. Eosinophilic spongiosis in bullous pemphigoid. Arch. Dermatol. 120: 1166-1168.
11. Natio, K., S. Morioka, S. Ikeda, and H. Ogawa. 1984. Experimental bullous pemphigoid in guinea pigs: the role of pemphigoid antibodies, complement, and migrating cells. J. Invest. Dermatol. 82: 227-230.
12. Nestor, M. S., A. J. Cochran, and A. R. Ahmed. 1987. Mononuclear cell infiltrates in bullous disease. J. Invest. Dermatol. 88: 172-175.
13. Wintroub, B. U., M. C. Mihm, Jr., E. J. Goetzl, N. A. Soter, and K.F. Austen. 1978. Morphologic and functional evidence for release of mast cell products in bullous pemphigoid. N. Engl. J. Med. 298: 417-421.
14. Iwatsuki, K., H. Tagami, and M. Yamada. 1983. Induction of leukocyte adherence at the basement membrane zone with subsequent activation of their metabolic pathway by pemphigoid antibodies and complement. Acta Derm. Venereol. 63: 495-500.
15. Liu, Z., L. A. Diaz, J. L. Troy, A. F. Taylor, D. E. Emery, J. A. Fairley, and G. J. Giudice. 1993. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J. Clin. Invest. 92: 2480-2488.
16. Liu, Z., G. J. Giudice, S. J. Swartz, J. A. Fairley, G. O. Till, J. L. Troy, and L. A. Diaz. 1995. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 95: 1539-1544.
17. Chen, R., G. Ning, M. L. Zhao, M. G. Fleming, L. A. Diaz, Z. Werb, and Z. Liu. 2001. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 108: 1151-1158.
18. Liu, Z., G. J. Giudice, X. Zhou, S. J. Swartz, J. L. Troy, J. A. Fairley, G. O. Till, and L. A. Diaz. 1997. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. Invest. 100: 1256-1263.
19. Liu, Z., X. Zhou, S. D. Shapiro, J. M. Shipley, S. S. Twining, L. A. Diaz, R. M. Senior, and Z. Werb. 2000. The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102: 647-655.
20. Daëron, M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15: 203-234.
21. Ravetch, J. V., and R. A. Clynes. 1998. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16: 421-432.
22. Takai, T. 2002. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 580: 580-592.
23. Flesch, B. K., and J. Neppert. 2000. Functions of the Fc receptors for immunoglobulin G. J. Clin. Lab. Anal. 14: 141-156.
24. Verbeek, J. S., W. L. Hazenbos, P. J. Capel, and J. G. van de Winkel. 1997. The role of FcR in immunity: lessons from gene targeting in mice. Res. Immunol. 148: 466-474.
25. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275-290.
26. Takai, T., M. Li, D. Sylvestre, R. A. Clynes, and J. V. Ravetch. 1994. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell 76: 519-529.
27. Takai, T., M. Ono, M. Hikida, H. Ohmori, and J. V. Ravetch. 1996. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379: 346-349.
28. Clynes, R., and J. V. Ravetch. 1995. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 3: 21-26.
29. Clynes, R., J. S. Maizes, R. Guinamard, M. Ono, T. Takai, and I.V. Ravetch. 1999. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189: 179-186.
30. Clynes, R., C. Dumitru, and J. V. Ravetch. 1998. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279: 1052-1054.
31. Suzuki, Y., I. Shirato, K. Okumura, J. V. Ravetch, T. Takai, Y. Tomino, and C. Ra. 1998. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. 54: 1166-1174.
32. Park, S. Y., S. Ueda, H. Ohno, Y. Hamano, M. Tanaka, T. Shiratori, T. Yamazaki, H. Arase, N. Arase, A. Karasawa, et al. 1998. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102: 1229-1238.
33. Watanabe, N., B. Akikusa, S. Y. Park, H. Ohno, L. Fossati, G. Vecchietti, J. E. Gessner, R. E. Schmidt, J. S. Verbeek, B. Ryffel, et al. 1999. Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fey receptors. Blood 94: 3855-3863.
34. Takai, T., M. Li, D. Sylvestre, R. A. Clynes, J. V. Ravetch. 1994. FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 76: 519-529.
35. Sylvestre, D. L., and J. V. Ravetch. 1994. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265: 1095-1098.
36. Schiller, C., I. Janssen-Graalfs, U. Baumann, K. Schwerter-Strumpf, S. Izui, T. Takai, R. E. Schmidt, and J. E. Gessner. 2000. Mouse FcγRII is a negative regulator of FcγRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur. J. Immunol. 30: 481-490.
37. Takai, T., M. Ono, M. Hikida, H. Ohmori, and J. V. Ravetch. 1996. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379: 346-349.
38. Kleinau, S., P. Martinsson, and B. Heyman. 2000. Induction and suppression of collagen-induced arthritis is dependent on distinct FCT receptors. J. Exp. Med. 191: 1611-1616.
39. b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189: 187-194.
40. Nakamura, A., T. Yuasa, A. Ujike, M. Ono, T. Nukiwa, J. V. Ravetch, and T. Takai. 2000. FCT receptor IIB-defident mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. 191: 899-906.
41. Holland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13: 277-285.
42. van Lent, P., K. C. Nabbe, P. Boross, A. B. Blom, J. Roth, A. Holthuysen, A. Sloetjes, S. Verbeek, and W. van den Berg. 2003. The inhibitory receptor FcγRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcγRI/III but also by efficient clearance and endocytosis of immune complexes. Am. J. Pathol. 163: 1839-1848.
43. Stefanescu, R. N., M. Olferiev, Y. Liu, and L. Pricop. 2004. Inhibitory Fcγ receptors: from gene to disease. J. Clin. Immunol. 24: 315-326.
44. Ujike, A., Y. Ishikawa, M. Ono, T. Yuasa, T. Yoshino, M. Fukumoto, J. V. Ravetch, and T. Takai. 1999. Modulation of immunoglobulin (Ig) E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J. Exp. Med. 189: 1573-1579.
45. Dopp, R., E. Schmidt, I. Chimanovitch, M. Leverkus, E. Brocker, and D. Zillikens. 2000. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J. Am. Acad. Dermatol. 42: 577-583.
46. Liu, Z., and L. A. Diaz. 2001. Bullous pemphigoid: end of the century overview. J. Dermatol. 28: 647-650.
47. Belaaouaj, A., R. McCarthy, M. Baumann, Z. Gao, T. J. Ley, S. N. Abraham, and S. D. Shapiro. 1998. Mice lacking neutrophil elastase reveal impaired host defense against Gram negative bacterial sepsis. Nat. Med. 4: 615-618.
48. Li, K., K. Tamai, E. M. L. Tan, and J. Uitto. 1993. Cloning of type XVII collagen: complementary and genomic DNA sequences of mouse 180-kilodalton bullous pemphigoid antigen (BPAG2) predict an interrupted collagenous domain, a transmembrane segment, and unusual features in the 5′-end of the gene and the 3′-untranslated region of the mRNA. J. Biol. Chem. 268: 8825-8834.
49. Liu, Z., L. A. Diaz, S. J. Swartz, J. A. Fairley, J. L Troy, and G. J. Giudice. 1995. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J. Immunol. 155: 5449-5454.
50. Bradley, P. P., D. A. Priebat, R. D. Christensen, and G. Rothstein. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78: 206-209.
51. Metcalf, J. A., J. I. Gallin, W. M. Nauseef, and R. K. Root. 1985. Laboratory Manual of Neutrophil Function. Raven Press, New York, pp. 2-10.
52. Wershil, B. K., Z. Wang, J. R. Jordon, and S. J. Galli. 1991. Recruitment of neutrophils during IgE-dependent cutaneous late phase responses in the mouse is mast cell dependent: partial inhibition of the reaction with antiserum against tumor necrosis factor-α. J. Clin. Invest. 87: 446-453.
53. Desrochers, P. E., K. Mookhtiar, H. E. Van Wart, K. A. Hasty, and S.J. Weiss. 1992. Proteolytic inactivation of α1-proteinase inhibitor and α1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J. Biol. Chem. 267: 5005-5012.
54. Liu, Z., S. D. Shapiro, X. Zhou, S. Twining, R. M. Senior, G. J. Giudice, J. A. Fairley, and L. A. Diaz. 2000. Neutrophil elastase plays a direct role in dermal-epidermal junction separation in experimental bullous pemphigoid. J. Clin. Invest. 105: 113-123.
55. Liu, Z., J. M. Shipley, T. H. Vu, X. Zhou, L. A. Diaz, Z. Werb, and R. M. Senior. 1998. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J. Exp. Med. 188: 475-482.
56. Li, N., M. Zhao, J. Hilario-Vargas, P. Prisayanh, S. Warren, L. A. Diaz, D. C. Roopenian, and Z. Liu. 2005. Complete FcRn dependence for IVIG therapy in autoimmune skin blistering diseases. J. Clin. Invest. 115: 3440-3450.
57. Hazenbos, W. L., I. A. Heijnen, D. Meyer, F. M. Hofhuis, C. R. Renardel de Lavalette, R. E. Schmidt, P. J. Capel, J. G. van de Winkel, J. E. Gessner, T. K. van den Berg, and J. S. Verbeek. 1998. Murine IgG1 complexes trigger immune effector functions predominantly via FcγRIII (CD 16). J. Immunol. 161: 3026-3032.
58. Gammon, W. R., C. C. Merritt, D. M. Lewis, W. M. Sams, Jr., J. R. Carlo, and C. E. Wheeler, Jr. 1982. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J. Invest. Dermatol. 78: 285-290.
59. Sitaru, C., E. Schmidt, S. Petermann, L. S. Munteanu, E. B. Brocker, and D. Zillikens. 2002. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J. Invest. Dermatol. 118:664-671.
60. Ghohestani, R. F., and J. Uitto. 2000. IgG autoantibodies to BP180 are directly pathogenic in human skin and induce sub-epidermal blisters: evidence using skin explant culture and SCID mouse grafted with human skin. FASEB J. 14: 1106.
61. McGrath, J. A., B. Gatalica, A. M. Christiano K. Li, K. Owaribe, J. R. McMillan, R. A. Eady, and J. Uitto. 1995. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat. Genet. 11: 83-86.
62. Vaisanen, L., C. Has, C. T. Franzke, T. Hurskainen, M. L. Tuomi, L. Bruckner-Tuderman, and K. Tasanen. 2005. Molecular mechanisms of junctional epidermolysis bullosa: Col 15 domain mutations decrease the thermal stability of collagen XVII. J. Invest. Dermatol. 125: 1112-1118.